NCT00784667View on ClinicalTrials.gov

Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib

PHASE2UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

February 28, 2011

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Cetuximab

400mg/m2 intravenously week 1, then 250 mg/m2 weekly intravenously

DRUG

Erlotinib

100mg orally daily continuously

Trial Locations (4)

3084

Austin Health, Melbourne

Unknown

Royal North Shore Hospital, Sydney

Queen Elizabeth Hospital, Adelaide

Ballarat Base Hospital, Ballarat

Sponsors

Lead Sponsor

Austin Health

Collaborators (1)

Ballarat Health Services
All Listed Sponsors
collaborator

Ballarat Health Services

OTHER

collaborator

Queen Elizabeth Hospital, Adelaide

UNKNOWN

collaborator

Royal North Shore Hospital

OTHER

lead

Austin Health

OTHER_GOV

NCT00784667 - Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib | Biotech Hunter | Biotech Hunter